Arvinas to Showcase Clinical Findings for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress on Parkinson's Disease and Movement Disorders®
Presentation of ARV-102: Arvinas, Inc. will present clinical data for ARV-102, a PROTAC LRRK2 degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders, including an oral presentation and an e-poster session.
About ARV-102 and Arvinas: ARV-102 is designed to target LRRK2, implicated in neurological diseases like Parkinson's. Arvinas is a biotechnology company focused on developing therapies that utilize protein degradation to treat various diseases.
Trade with 70% Backtested Accuracy
Analyst Views on ARVN
About ARVN
About the author
Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL Expected in 2026
- Clinical Trial Launch: Arvinas plans to initiate a combination clinical trial of ARV-393 and glofitamab in 2026, aiming to provide a chemotherapy-free treatment option for patients with diffuse large B-cell lymphoma, addressing a significant unmet medical need.
- Significant Efficacy: In a high-grade B-cell lymphoma model, the combination of ARV-393 and glofitamab achieved an 81% tumor growth inhibition rate, demonstrating substantial synergistic anti-tumor effects that could offer a more effective treatment option for patients.
- Mechanistic Research Support: RNA sequencing analysis revealed that ARV-393 upregulates CD20 expression and promotes interferon signaling pathways, indicating a strong mechanistic rationale for its combination with glofitamab, providing theoretical support for future clinical applications.
- Market Potential: As demand for chemotherapy-free treatment options increases, this research by Arvinas not only aims to improve patient quality of life but also positions the company to capture market share in the competitive biopharmaceutical landscape.
Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL, Expected in 2026
- Trial Initiation: Arvinas plans to initiate a combination clinical trial of ARV-393 and glofitamab in 2026, aiming to provide a chemotherapy-free treatment option for patients with diffuse large B-cell lymphoma, addressing a significant unmet medical need.
- Preclinical Data: In a high-grade B-cell lymphoma model, the combination of ARV-393 and glofitamab achieved an 81% tumor growth inhibition rate, demonstrating significant synergistic anti-tumor effects and indicating the clinical potential of this combination.
- Dose Optimization: At a higher dose of 6 mg/kg for ARV-393, the combination therapy showed increased tumor regression rates, with complete regression observed in 10 out of 10 mice, highlighting the efficacy and safety of this treatment approach.
- Mechanistic Insights: RNA sequencing revealed that ARV-393 upregulates CD20 expression and enhances interferon signaling pathways, which may provide a mechanistic basis for its synergistic effects with glofitamab, further supporting its clinical rationale.
Arvinas to Participate in Piper Sandler Healthcare Conference on December 4
- Executive Participation: Arvinas' Chief Medical Officer Noah Berkowitz and Chief Financial Officer Andrew Saik will engage in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4 in New York, showcasing the company's cutting-edge advancements in biotechnology.
- Clinical Development Progress: Arvinas is advancing multiple investigational drugs, including ARV-102 targeting neurodegenerative disorders and ARV-393 for relapsed/refractory non-Hodgkin lymphoma, highlighting the company's innovative potential in the targeted protein degradation space.
- Technological Platform Advantage: Through its PROTAC protein degrader platform, Arvinas is developing therapies designed to effectively degrade disease-causing proteins, aiming to improve patient quality of life and reflecting the company's strategic positioning in treating severe diseases.
- Market Positioning: Arvinas focuses on developing treatments for various life-threatening diseases, indicating its significant role in the biopharmaceutical industry, particularly in the innovative drug development for cancer and neurodegenerative disorders.
Arvinas Unveils Preclinical Findings for ARV-806 Showcasing Strong and Unique Efficacy in KRAS G12D-Mutated Cancer Models at the 2025 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Treatments
ARV-806 Efficacy: ARV-806, a PROTAC KRAS G12D degrader, showed significant tumor growth inhibition and robust degradation of KRAS G12D in preclinical models of pancreatic, colorectal, and lung cancers, demonstrating its potential as a best-in-class therapy for these cancers.
Differentiation from Other Agents: The data presented highlight ARV-806's superior potency and durability compared to other G12D targeting agents, with over 25-fold greater potency in reducing cancer cell proliferation and over 40-fold higher potency in degrading KRAS G12D protein.
Clinical Development: Arvinas is currently evaluating ARV-806 in a Phase 1 clinical trial for patients with KRAS G12D-mutated advanced solid tumors, indicating a commitment to addressing high unmet needs in this area.
Innovative Approach: The use of targeted protein degradation through ARV-806 aims to overcome historical challenges in treating undruggable KRAS mutations, potentially leading to meaningful benefits for patients with these mutations.
Patient-Reported Outcomes from the VERITAC-2 Trial Indicate Clinical Benefits of Vepdegestrant for Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer After Endocrine Therapy
Clinical Trial Results: The Phase 3 VERITAC-2 trial showed that vepdegestrant significantly improved patient-reported outcomes, delaying deterioration in quality of life, pain, and daily functioning compared to fulvestrant in patients with ESR1-mutated ER+/HER2- advanced breast cancer.
Potential Treatment Option: Vepdegestrant is being developed as a monotherapy for advanced breast cancer and has received Fast Track designation from the FDA, indicating its potential as a meaningful treatment option for patients previously treated with endocrine therapy.
Looking Ahead: 7 Analyst Predictions for Arvinas
Analyst Ratings Overview: In the latest quarter, 7 analysts provided mixed ratings for Arvinas, with 3 bullish, 3 somewhat bullish, and 1 bearish, reflecting a downward trend in price targets averaging $13.57, which is 17.76% lower than the previous average.
Recent Analyst Actions: Analysts from various firms have lowered their price targets for Arvinas, with notable reductions from Goldman Sachs and BTIG, indicating a cautious outlook on the company's performance.
Financial Performance Insights: Arvinas has experienced a significant decline in revenue growth of approximately -70.72% over the past three months, while its net margin is notably high at -273.21%, suggesting challenges in profitability.
Debt Management and Ratios: The company maintains a low debt-to-equity ratio of 0.02, indicating a conservative approach to debt financing, although its return on equity (ROE) and return on assets (ROA) are below industry averages, highlighting potential efficiency issues.
Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL Expected in 2026
- Clinical Trial Launch: Arvinas plans to initiate a combination clinical trial of ARV-393 and glofitamab in 2026, aiming to provide a chemotherapy-free treatment option for patients with diffuse large B-cell lymphoma, addressing a significant unmet medical need.
- Significant Efficacy: In a high-grade B-cell lymphoma model, the combination of ARV-393 and glofitamab achieved an 81% tumor growth inhibition rate, demonstrating substantial synergistic anti-tumor effects that could offer a more effective treatment option for patients.
- Mechanistic Research Support: RNA sequencing analysis revealed that ARV-393 upregulates CD20 expression and promotes interferon signaling pathways, indicating a strong mechanistic rationale for its combination with glofitamab, providing theoretical support for future clinical applications.
- Market Potential: As demand for chemotherapy-free treatment options increases, this research by Arvinas not only aims to improve patient quality of life but also positions the company to capture market share in the competitive biopharmaceutical landscape.
Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL, Expected in 2026
- Trial Initiation: Arvinas plans to initiate a combination clinical trial of ARV-393 and glofitamab in 2026, aiming to provide a chemotherapy-free treatment option for patients with diffuse large B-cell lymphoma, addressing a significant unmet medical need.
- Preclinical Data: In a high-grade B-cell lymphoma model, the combination of ARV-393 and glofitamab achieved an 81% tumor growth inhibition rate, demonstrating significant synergistic anti-tumor effects and indicating the clinical potential of this combination.
- Dose Optimization: At a higher dose of 6 mg/kg for ARV-393, the combination therapy showed increased tumor regression rates, with complete regression observed in 10 out of 10 mice, highlighting the efficacy and safety of this treatment approach.
- Mechanistic Insights: RNA sequencing revealed that ARV-393 upregulates CD20 expression and enhances interferon signaling pathways, which may provide a mechanistic basis for its synergistic effects with glofitamab, further supporting its clinical rationale.
Arvinas to Participate in Piper Sandler Healthcare Conference on December 4
- Executive Participation: Arvinas' Chief Medical Officer Noah Berkowitz and Chief Financial Officer Andrew Saik will engage in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4 in New York, showcasing the company's cutting-edge advancements in biotechnology.
- Clinical Development Progress: Arvinas is advancing multiple investigational drugs, including ARV-102 targeting neurodegenerative disorders and ARV-393 for relapsed/refractory non-Hodgkin lymphoma, highlighting the company's innovative potential in the targeted protein degradation space.
- Technological Platform Advantage: Through its PROTAC protein degrader platform, Arvinas is developing therapies designed to effectively degrade disease-causing proteins, aiming to improve patient quality of life and reflecting the company's strategic positioning in treating severe diseases.
- Market Positioning: Arvinas focuses on developing treatments for various life-threatening diseases, indicating its significant role in the biopharmaceutical industry, particularly in the innovative drug development for cancer and neurodegenerative disorders.
Arvinas Unveils Preclinical Findings for ARV-806 Showcasing Strong and Unique Efficacy in KRAS G12D-Mutated Cancer Models at the 2025 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Treatments
ARV-806 Efficacy: ARV-806, a PROTAC KRAS G12D degrader, showed significant tumor growth inhibition and robust degradation of KRAS G12D in preclinical models of pancreatic, colorectal, and lung cancers, demonstrating its potential as a best-in-class therapy for these cancers.
Differentiation from Other Agents: The data presented highlight ARV-806's superior potency and durability compared to other G12D targeting agents, with over 25-fold greater potency in reducing cancer cell proliferation and over 40-fold higher potency in degrading KRAS G12D protein.
Clinical Development: Arvinas is currently evaluating ARV-806 in a Phase 1 clinical trial for patients with KRAS G12D-mutated advanced solid tumors, indicating a commitment to addressing high unmet needs in this area.
Innovative Approach: The use of targeted protein degradation through ARV-806 aims to overcome historical challenges in treating undruggable KRAS mutations, potentially leading to meaningful benefits for patients with these mutations.
Patient-Reported Outcomes from the VERITAC-2 Trial Indicate Clinical Benefits of Vepdegestrant for Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer After Endocrine Therapy
Clinical Trial Results: The Phase 3 VERITAC-2 trial showed that vepdegestrant significantly improved patient-reported outcomes, delaying deterioration in quality of life, pain, and daily functioning compared to fulvestrant in patients with ESR1-mutated ER+/HER2- advanced breast cancer.
Potential Treatment Option: Vepdegestrant is being developed as a monotherapy for advanced breast cancer and has received Fast Track designation from the FDA, indicating its potential as a meaningful treatment option for patients previously treated with endocrine therapy.
Looking Ahead: 7 Analyst Predictions for Arvinas
Analyst Ratings Overview: In the latest quarter, 7 analysts provided mixed ratings for Arvinas, with 3 bullish, 3 somewhat bullish, and 1 bearish, reflecting a downward trend in price targets averaging $13.57, which is 17.76% lower than the previous average.
Recent Analyst Actions: Analysts from various firms have lowered their price targets for Arvinas, with notable reductions from Goldman Sachs and BTIG, indicating a cautious outlook on the company's performance.
Financial Performance Insights: Arvinas has experienced a significant decline in revenue growth of approximately -70.72% over the past three months, while its net margin is notably high at -273.21%, suggesting challenges in profitability.
Debt Management and Ratios: The company maintains a low debt-to-equity ratio of 0.02, indicating a conservative approach to debt financing, although its return on equity (ROE) and return on assets (ROA) are below industry averages, highlighting potential efficiency issues.
